NCT05119933: An overdue trial by Shanghai YingLi Pharmaceutical Co. Ltd.
This trial is overdue. It was due to report 10 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT05119933 |
|---|---|
| Title | A Phase 1/2, Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 9, 2021 |
| Completion date | June 1, 2023 |
| Required reporting date | May 31, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 300 |